Clinical Trial Update: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab beta plus fruquintinib with or without immune checkpoint inhibitors as first-line therapy for RAS/BRAF wild-type unresectable…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab beta (cetuximab beta)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Zhejiang University | Conditions: Colorectal Neoplasms, RAS | Phase 2 | Status: RECRUITING